-
Study aim
-
Evaluation of the effects of Licorice on clinical symptoms and laboratory signs in patients with COVID-19
-
Design
-
Controlled clinical trial with parallel group, open-label, phase 3, 60 patients, simple randomized method
-
Settings and conduct
-
This study will be conducted at the Shahid Mohammadi Hospital, Hormozgan University of Medical Sciences, Bandar Abbas.The study population is 60 patients with COVID-19 (30 patients in control group and 30 in study group).
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria: Patients with positive polymerase chain reaction (PCR) test for COVID-19 or/and lung involvement in imaging, age ≥18 years, primary clinical symptoms, hospitalization, and signing informed consent.
Exclusion Criteria: Patients with underlying diseases, including heart disease, chronic hypertension, severe renal and liver failure, and thyroid disorders, Use of warfarin, SSRIs, MAOIs, diuretics, corticosteroids, and antiarrhythmic drugs, history of drug allergy, and pregnancy and breastfeeding
-
Intervention groups
-
Group A will be patients receiving standard treatment of COVID-19 according to the Ministry of Health's protocol. Group B will be patients receiving, in addition to the standard treatment, a licorice-based herbal tablet, at a dose of 760 mg three times a day for a period of 14 days.
-
Main outcome variables
-
Checking the fever, respiratory rate, O2 saturation
Evaluation of white blood cell count, C-reactive protein
Occurrence of adverse drug reactions